In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- Paragangliomas

  • End date
    Jun 30, 2025
  • participants needed
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 31 December 2021


Qualitative and quantitative biomarker of response to radiotherapy is needed in paragangliomas. We aim at assessing the added value of 1H-SRM for the evaluation of early response to EBR therapy in patients with cervical SDHx PGL.


Paragangliomas (PGL) are rare neuroendocrine tumors inherited in 40% of cases. SDHx genes (SDHA, SDHB, SDHC, SDHD), encoding the 4 subunits of the mitochondrial enzyme succinate dehydrogenase (SDH), are the most frequently involved.

Accumulation of succinate, the substrate for SDH, is a very specific biomarker for these mutations. Recently, we have demonstrated the feasability of detecting and quantifying succinate in tumors in vivo, by magnetic resonance spectroscopy (1H-SRM).

Patients carrying these mutations frequently develop cervical PGL for which the treatment of choice is external beam radiation therapy (EBR).

The objective of this project is to determine the feasibility of using 1H-SRM for the evaluation of early response to EBR therapy in patients with cervical SDHx PGL.

Condition Paraganglioma of Head and Neck
Treatment 1H-Spectroscopy MRI
Clinical Study IdentifierNCT04583384
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on31 December 2021


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Signed informed consent
Patient with cervical PGL with planning of treatment with EBR
Patient with an SDHx mutation or unknown genetic status
Patient affiliated to a social security scheme

Exclusion Criteria

Pregnant woman
Contraindication to MRI (implantable device, etc.)
Impossibility of lying down without movement for 45 minutes (hyperalgesic patient, claustrophobia, etc.)
PPGL having previously been the subject of local (excluding surgery) or systemic treatment
PPGL <1 cm longest axis
Patient under guardianship or curatorship
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note